Product information
From Health Canada
Note - The product information found within this database originates from organizations not subject to the Official Languages Act and is available in the language in which it was written and submitted to Health Canada.
Note - The market status of a product is now available in the LNHPD and identifies if a product is "marketed" or "not marketed" in Canada. Product licence holders may voluntarily provide the Natural and Non-Prescription Health Products Directorate (NNHPD) with information about whether their product is currently available to Canadian consumers. Where no information has been provided, the default status is "not marketed". The "current status" field remains unaffected and will continue to indicate the status of the product licence (i.e., active, discontinued, stop sale, cancelled, or suspended). Note that where a licence has been suspended, cancelled or under stop sale, the product cannot be legally sold in Canada.
Product licence holders - if you wish to update a product's market status, you are invited to complete the Natural Health Products Market Notification Web Form. As with all other notifications, there is no current service standard. The NNHPD will process the market status update as soon as feasible, based on its available resources. As a reminder, market notification is voluntary; therefore, a licence holder is not required to wait for the LNHPD to be updated before a licensed product is sold in Canada. As such, products that are identified in the LNHPD as "not marketed" may still be sold in Canada.
- Natural Product Number (NPN):
- 80127695
- Market status:
- Not Marketed
- Licence Status:
- Active
- Brand name(s):
-
Diosmin 300 mg + Hesperidin 33 mg
;
Cell DioHesp ;
Cell DiosHesp 333 mg ;
Cell Diosmin-Hesperidin 333 mg ;
Diosmin and Hesperidin 333 mg - Licence holder:
- CellChem Pharmaceuticals Inc.
- Dosage Form:
- Tablet
- Recommended route of administration:
-
Oral
Sub population (Sub Pop.) | Quantity (Qty) | Frequency (Freq.) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sub Pop. | Age | Min. | Max. | UoM Footnote1 Age | Qty | Min. | Max. | UoM Qty | Freq. | Min. | Max. | UoM Freq. |
Adults | 18 | Years | 1.0 | tablet | 3 | daily | ||||||
- Recommended use or purpose:
- Helps relieve symptoms of non-complicated chronic venous insufficiency (CVI) such as sensation of swelling, varicose veins, feeling of heaviness, pain, tiredness and itching.
- Risk Information:
- Cautions and Warnings
- Consult a physician if symptoms persist or worsen. Consult a physician prior to use if you are pregnant or breastfeeding. Consult a physician prior to use if you are taking any prescription medications. Keep out of reach of children.
- Known Adverse Reactions
- Some people may experience headache, dizziness, itchiness, gastric irritation or gastric pains.
Medicinal ingredients | Quantity (Qty) | Extract | Potency |
---|---|---|---|
(2S)-7-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one |
33.0 mg
|
||
5-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(O6-alpha-L-rhamnopyranosyl-beta-D-glucopyranosyloxy)chromen-4-one |
300.0 mg
|
- List of non-medicinal ingredients:
-
- Calcium phosphate, dibasic
- Colloidal silica gel
- Colloidal silicon dioxide
- Gelatin
- Iron oxide (Fe2O3)
- Iron oxide yellow
- Magnesium stearate
- Polacrilin Potassium
- Polyethylene glycol
- Sodium benzoate
- Sodium lauryl sulfate
- Talc
- Titanium dioxide
- Date of licensing:
- 2023-10-31
- Revised date of licence:
Application information
Related information
Contact us
For technical support or if you have general questions concerning the content of this database, please contact the Natural Health Products Directorate (NHPD).